Laurus Labs gets DRDO license to manufacture 2-DG

Laurus Labs Ltd on Friday announced that it has received the license from the Defence Research and Development Organisation (DRDO) to manufacture and market its Covid drug, 2-Deoxy-D-Glucose (2-DG).

2-DG has been given emergency approval by the Drug Controller General of India for use on Covid-19 patients in India.

Laurus Labs, a leading research and development-driven and fully integrated pharmaceutical and biotech company, has already applied to the Central Drugs Standard Control Organisation for emergency use authorisation (EUA) for 2-DG.

An adjunct therapy in moderate to severe Covid-19 cases, 2-DG was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in collaboration with Dr Reddy's Laboratories.